# Phase 1 melanoma trials recruiting: 71 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 71 trials in phase 1 for melanoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 melanoma trials: 71 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/melanoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 71
- Recruiting or not yet: 71
- Read on: November 19, 2026

## Trials

The 25 newest of 71, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| October 5, 2026 | NCT07857616 | SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non... | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857616) |
| September 24, 2026 | NCT07838974 | Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older | University of Southern California | Phase 1 | Not yet recruiting | Melanoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838974) |
| July 10, 2026 | NCT07694414 | Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events | Sponsor not shown (see the record) | Phase 1 | Recruiting | Immune-Related Adverse Events | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694414) |
| June 5, 2026 | NCT07628894 | Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy | City of Hope Medical Center | Phase 1 | Not yet recruiting | Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628894) |
| May 20, 2026 | NCT07600476 | A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid... | Kupando GmbH | Phase 1 | Recruiting | Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin, Basal... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600476) |
| May 12, 2026 | NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | Biocon Biologics UK PLC | Phase 1 | Recruiting | Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581509) |
| April 9, 2026 | NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519655) |
| April 8, 2026 | NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | Shanghai Henlius Biotech | Phase 1 | Recruiting | Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC) | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518043) |
| March 30, 2026 | NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Uveal Melanoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501117) |
| March 17, 2026 | NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | Biocon Biologics UK PLC | Phase 1 | Recruiting | Melanoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476326) |
| March 16, 2026 | NCT07475572 | Pharmacokinetic Similarity Study to Compare AVT32-DRL\_PB With Keytruda® in Participants With Fully Resected Melanoma | Alvotech Swiss AG | Phase 1 | Recruiting | Melanoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475572) |
| March 3, 2026 | NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Melanoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444606) |
| January 29, 2026 | NCT07376707 | A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 | Recruiting | CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer) | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376707) |
| January 6, 2026 | NCT07320222 | CARE-Melanoma Trial | McMaster University | Phase 1 | Not yet recruiting | Melanoma (Skin Cancer) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07320222) |
| January 5, 2026 | NCT07317505 | A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors | Conjupro Biotherapeutics, Inc. | Phase 1 | Recruiting | Cancer, Cancer (Solid Tumors) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07317505) |
| December 3, 2025 | NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | The First Affiliated Hospital of Xinxiang Medical College | Phase 1 | Recruiting | Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer, Cancer Treatment, Immunotherapy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260591) |
| November 28, 2025 | NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | AccSalus Biosciences, Inc. | Phase 1 | Not yet recruiting | Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252661) |
| November 24, 2025 | NCT07244835 | A Study of DEG6498 in Participants With Solid Tumors | Degron Therapeutics Co. | Phase 1 | Recruiting | Malignant Neoplasms | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244835) |
| November 20, 2025 | NCT07237594 | IL-17 Blockade to Decrease irAEs (REPLAY) | Duke University | Phase 1 | Recruiting | Metastatic Melanoma | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07237594) |
| November 4, 2025 | NCT07224425 | A Study of BI 3810944 in Patients With Advanced Cancer | Boehringer Ingelheim | Phase 1 | Recruiting | Solid Tumours, Melanoma | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224425) |
| October 2, 2025 | NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis | St Vincent's Hospital, Sydney | Phase 1 | Recruiting | Uveal Melanoma, Metastatic | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07203391) |
| September 19, 2025 | NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma | Vastra Gotaland Region | Phase 1 | Not yet recruiting | Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07183852) |
| September 17, 2025 | NCT07177937 | A Study of DXC014 in Patients With Advanced Solid Tumors. | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 | Recruiting | Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177937) |
| August 6, 2025 | NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | West China Hospital | Phase 1 | Recruiting | HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer), Pancreatic Ductal... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106827) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 6 |
| Biocon Biologics UK PLC | 2 |
| Vastra Gotaland Region | 2 |
| Washington University School of Medicine | 2 |
| Hefei TG ImmunoPharma Co., Ltd. | 2 |
| Duke University | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| SystImmune Inc. | 2 |
| Degron Therapeutics Co. | 1 |
| McMaster University | 1 |
| Shandong Boan Biotechnology Co., Ltd | 1 |
| MonTa Biosciences ApS | 1 |
| [Alvotech Swiss AG](https://specstream.ai/data/clinical-trials/company/alvotech-swiss-ag) | 1 |
| Novelty Nobility, Inc. | 1 |
| [Pierre Fabre Medicament](https://specstream.ai/data/clinical-trials/company/pierre-fabre-medicament) | 1 |
| Conjupro Biotherapeutics, Inc. | 1 |
| ViroMissile, Inc. | 1 |
| West China Hospital | 1 |
| Memgen, Inc. | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Chiome Bioscience Inc. | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| Suzhou BlueHorse Therapeutics Co., Ltd. | 1 |
| AccSalus Biosciences, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 43 |
| China | 11 |
| Australia | 7 |
| Spain | 5 |
| Denmark | 4 |
| Brazil | 2 |
| Ukraine | 2 |
| France | 2 |
| Italy | 2 |
| Germany | 2 |
| Netherlands | 2 |
| Taiwan | 1 |
| United Kingdom | 1 |
| Japan | 1 |
| Canada | 1 |
| Chile | 1 |
| Georgia | 1 |
| Moldova | 1 |
| Romania | 1 |
| Serbia | 1 |
| South Africa | 1 |
| Turkey (Türkiye) | 1 |
| Puerto Rico | 1 |
| South Korea | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water heater installers in the United States](https://specstream.ai/data/businesses/water-heater-installers/united-states)
- [Afghani restaurants in the United States](https://specstream.ai/data/businesses/afghani-restaurants/united-states)
- [Australian restaurants in the United States](https://specstream.ai/data/businesses/australian-restaurants/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
- [Caribbean restaurants in the United States](https://specstream.ai/data/businesses/caribbean-restaurants/united-states)
